Zobrazeno 1 - 3
of 3
pro vyhledávání: '"James Tislow"'
Publikováno v:
Pulmonary Circulation
Pulmonary Circulation, Vol 8 (2018)
Pulmonary Circulation, Vol 8 (2018)
Treatment with endothelin receptor antagonists (ERA) can result in adverse hepatic effects in patients with pulmonary arterial hypertension (PAH). We evaluated the hepatic safety of ambrisentan (ABS), an ERA, used as monotherapy, or with tadalafil (T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c30441bca9ff0efd79154d4908ddf252
https://doi.org/10.1177/2045894018797273
https://doi.org/10.1177/2045894018797273
Autor:
Aryeh Fischer, James Tislow, Christopher P. Denton, Hunter Gillies, Marco Matucci-Cerinic, Steven D. Nathan, Christiana Blair
Publikováno v:
Respiratory Medicine. 117:254-263
Objective Pulmonary arterial hypertension (PAH) is a condition which may lead to right ventricular failure and early mortality and is an important complication in patients with connective tissue disease (CTD). Previously, the endothelin A selective r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d40fa34383381d44bba5596606d9be9
https://doi.org/10.1016/j.rmed.2016.06.018
https://doi.org/10.1016/j.rmed.2016.06.018
Autor:
Martine Allard, Shelley Shapiro, Jeremy Feldman, Ronald J. Oudiz, Hunter Gillies, Christiana Blair, Fernando Torres, Anne Keogh, James Tislow
Publikováno v:
Respiratory medicine. 126
Objective Pulmonary arterial hypertension (PAH) is a condition which may lead to right ventricular failure and premature death. While recent data supports the initial combination of ambrisentan (a selective ERA) and tadalafil (a PDE5i) in functional
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::977283f4af239be2800013526832af60
https://pubmed.ncbi.nlm.nih.gov/28427554
https://pubmed.ncbi.nlm.nih.gov/28427554